Cardiac Valve and Other Major Cardiothoracic Procedures DRG Reimbursement

DRG 217 includes cardiac valve and other major cardiothoracic procedures performed with cardiac catheterization when a Complication or Comorbidity is present; it encompasses high-acuity surgical care combined with catheter-based diagnostic or interventional work. This matters for inpatient reimbursement because grouping under this Diagnosis-Related Group influences Medicare prospective payment for resource-intensive cardiac surgical admissions.

DRG 217 Overview

DRG 217 covers hospital admissions for cardiac valve and other major cardiothoracic procedures performed with cardiac catheterization when a Complication or Comorbidity is present. This Diagnosis-Related Group captures high-resource surgical and perioperative care, including valve repair or replacement combined with diagnostic or interventional catheterization. It matters for Medicare payment because case assignment to this DRG influences inpatient prospective payment rates and reimbursement for complex cardiac surgical episodes. Accurate clinical documentation and coding of procedures and Complications or Comorbidities determine grouping and impact payment.

Acute procedural and perioperative safety studies assessing novel valve repair or replacement techniques combined with intraoperative cardiac catheterization: These trials focus on immediate outcomes such as hemodynamic stability, procedure-related complications (bleeding, stroke, conduction disturbances), and ICU length of stay in adult patients undergoing open or hybrid cardiac valve procedures that require concurrent diagnostic or interventional catheterization. They are relevant because this DRG captures high-acuity operative episodes where perioperative complications drive costs and resource utilization, informing risk mitigation strategies and short-term reimbursement considerations.
Comparative effectiveness trials comparing different surgical strategies or timing of catheterization in high-risk cohorts (for example, elderly patients, those with multivalvular disease, or significant comorbid coronary artery disease): These studies evaluate outcomes such as 30- and 90-day mortality, major adverse cardiac and cerebrovascular events, transfusion rates, and readmission, enrolling patients who require both major cardiothoracic surgery and catheter-based coronary assessment or intervention. Findings directly inform clinical pathways and payer decisions about bundled payment models, appropriate use criteria for concurrent catheterization, and resource allocation for patients who typically consume substantial inpatient services.
Post-discharge outcomes and health services research examining long-term functional status, readmissions, and cost-effectiveness of rehabilitation or coordinated care models after cardiac valve procedures with catheterization: These observational cohorts and pragmatic trials follow patients after hospital discharge to measure quality of life, rates of late complications (prosthetic dysfunction, endocarditis, heart failure exacerbation), and utilization of outpatient cardiology and cardiac rehabilitation services. Such research is important to providers and payers because it identifies opportunities to reduce readmissions, optimize post-acute care pathways, and improve value for a population with high upfront surgical costs and significant downstream service needs.

Acute procedural and perioperative safety studies assessing novel valve repair or replacement techniques combined with intraoperative cardiac catheterization: These trials focus on immediate outcomes such as hemodynamic stability, procedure-related complications (bleeding, stroke, conduction disturbances), and ICU length of stay in adult patients undergoing open or hybrid cardiac valve procedures that require concurrent diagnostic or interventional catheterization. They are relevant because this DRG captures high-acuity operative episodes where perioperative complications drive costs and resource utilization, informing risk mitigation strategies and short-term reimbursement considerations.
Comparative effectiveness trials comparing different surgical strategies or timing of catheterization in high-risk cohorts (for example, elderly patients, those with multivalvular disease, or significant comorbid coronary artery disease): These studies evaluate outcomes such as 30- and 90-day mortality, major adverse cardiac and cerebrovascular events, transfusion rates, and readmission, enrolling patients who require both major cardiothoracic surgery and catheter-based coronary assessment or intervention. Findings directly inform clinical pathways and payer decisions about bundled payment models, appropriate use criteria for concurrent catheterization, and resource allocation for patients who typically consume substantial inpatient services.
Post-discharge outcomes and health services research examining long-term functional status, readmissions, and cost-effectiveness of rehabilitation or coordinated care models after cardiac valve procedures with catheterization: These observational cohorts and pragmatic trials follow patients after hospital discharge to measure quality of life, rates of late complications (prosthetic dysfunction, endocarditis, heart failure exacerbation), and utilization of outpatient cardiology and cardiac rehabilitation services. Such research is important to providers and payers because it identifies opportunities to reduce readmissions, optimize post-acute care pathways, and improve value for a population with high upfront surgical costs and significant downstream service needs.

OpenPayer

Summary & Overview

Cardiac Valve and Other Major Cardiothoracic Procedures with Cardiac Catheterization with CC: Inpatient Reimbursement Overview

DRG 217 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes